Author: support@webspeakmedia.com

Sustained-release drug delivery targets pediatric inherited retinal disease

Sustained-release drug delivery targets pediatric inherited retinal disease For many children, inherited retinal diseases begin early in life, slowly taking away vision with no approved drug therapies available to slow or stop the damage. PolyActiva and RareSight are now working together to address that, collaborating on the development of first-in-class pharmacologic treatments for rare pediatric inherited..

PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases

FORT WORTH, Texas & MELBOURNE, Australia & MENLO PARK, Calif.–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ophthalmology-focused life sciences company committed to advancing therapies for inherited retinal diseases (IRDs), today announced a strategic..

Entrepreneur Pushes for New Treatments for Childhood Eye Diseases

The AlmanacEntrepreneur Pushes for New Treatments for Childhood Eye DiseasesAuthor: Arden Margulis ‘Kids get the leftovers …I thought it’s backwards,’ Caricchio said. Carmen Caricchio is a Menlo Park resident who founded RareSight, which aims to find a treatment for childhood inherited retinal diseases. Courtesy Carmen Caricchio. Menlo Park resident Carmen..

PolyActiva, RareSight to Collaborate on Rare Pediatric Retinal Diseases

Market Scope PolyActiva, RareSight to Collaborate on Rare Pediatric Retinal DiseasesAuthor: Jennie Crabbe Australia’s PolyActiva announced Nov. 5 that it would collaborate with RareSight, of Menlo Park, California, an ophthalmology-focused life sciences company committed to advancing therapies for rare pediatric retinal diseases. The collaboration will leverage PolyActiva’s Prezia sustained-release intravitreal drug..

PolyActiva and RareSight to advance long-acting therapies for pediatric IRDs

Eyes On Eyecare GlancePolyActiva and RareSight to advance long-acting therapies for pediatric IRDsAuthor: Alex Delaney-Gesing PolyActiva is collaborating with RareSight, Inc. to develop targeted therapeutics specifically designed for rare pediatric retinal diseases with no currently-approved treatments. First, a look at RareSight. This ophthalmic-based life sciences company is focused on accelerating the diagnosis..

PolyActiva and RareSight Join Forces to Target Rare Pediatric Retinal Diseases

In a move that could reshape how IRDs are treated, two innovative companies are joining forces to make long-lasting vision therapies a reality. 

PolyActiva (Victoria, Australia) and RareSight (California, USA) have announced a strategic collaboration to co-develop sustained-release therapies for rare pediatric retinal diseases, marking PolyActiva’s expansion into new ophthalmic indications beyond glaucoma.

PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases

Partnership Leverages PolyActiva’s PREZIA™ Drug Delivery Platform Technology and RareSight’s Expertise in Rare Diseases to Advance Novel Sustained Release Ocular Implants FORT WORTH, Texas & MELBOURNE, Australia & MENLO PARK, Calif.–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions,..